Kos at hold/high risk by Citigroup

Kos Pharmaceuticals Inc. was given a hold/high risk rating and a new price target of $49 by Citigroup Investment Research analyst Andrew Swanson on the company's disappointing fourth-quarter results. Adjusted earnings per share of $0.71 were lower than Citigroup's forecast of $0.81 and consensus of $0.80. Total revenues, however, came in ahead of the analyst's forecast, but the cholesterol franchise decelerated with sales of $149.5 million compared to Citigroup's $156 million estimate. Shares of the Cranbury, N.J., pharmaceutical company were up 90 cents, or 2.17%, at $42.29 on volume of 1,053,938 shares versus the three-month running average of 858,840 shares. (Nasdaq: KOSP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.